Premium
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT
Author(s) -
McLornan Donal P.,
Malpassuti Vittoria,
LippinkhofKozijn Anne,
Potter Victoria,
Beelen Dietrich,
Bunjes Donald,
Sengeloev Henrik,
Radujkovic Aleksandar,
Passweg Jakob,
Chalandon Yves,
Kröger Nicolaus,
Wulf Gerald G.,
Johansson JanErik,
Ciceri Fabio,
Bornhäuser Martin,
Holler Ernst,
Guffroy Blandine,
Martin Sonja,
Neubauer Andreas,
Gramatski Martin,
Robin Marie,
Iacobelli Simona,
Hayden Patrick,
Hernández Boluda Juan C.,
Czerw Tomasz,
YakoubAgha Ibrahim
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16537
Subject(s) - medicine , myeloproliferative neoplasm , asymptomatic , thrombocytosis , transplantation , myelofibrosis , stem cell , hematology , disease , hematopoietic stem cell transplantation , haematopoiesis , oncology , retrospective cohort study , immunology , bone marrow , platelet , biology , genetics
Summary Myeloproliferative Neoplasm (MPN), unclassifiable (MPN‐U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU‐U. Allogeneic Haematopoietic Cell Transplantation (allo‐HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN‐U undergoing allo‐HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.